Replimune Group Inc (REPL)

$8.99 +0.01 (0.11%)
Market Cap 704.42M
Revenue (ttm) 0.00
Net Income (ttm) -247.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.18
Volume 1,743,300
Avg Vol 5,957,462
Day's Range N/A - N/A
Shares Out 78.44M
Stochastic %K 64%
Beta 0.80
Analysts Strong Sell
Price Target $11.50

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express a...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 222 9600
Address:
500 Unicorn Park Drive, Suite 303, Woburn, United States
TwongStocks
TwongStocks Nov. 14 at 1:43 PM
$REPL RTW filed a new 13G this morning disclosing beneficial ownership in REPL https://www.sec.gov/Archives/edgar/data/1493215/000149321525000047/xslSCHEDULE_13G_X01/primary_doc.xml 6,395,732 shares, 8.2%
0 · Reply
smart500
smart500 Nov. 13 at 9:03 PM
$REPL classic Yee Haw gitty up horse chart. Let's ride her to the 🌜😆
0 · Reply
_ReddBullyz
_ReddBullyz Nov. 12 at 3:05 PM
Picked up on some of @Invinc1ble calls lately and they’ve been 🔥 If you trade, he’s definitely worth a follow💯 $DNLI $GWH $IPDN $REPL Monitor;
0 · Reply
patatechaude
patatechaude Nov. 12 at 2:34 PM
$REPL Makary might go down with Prasad. He needs to let go.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 12 at 11:31 AM
WATCHLIST NOV 12 2025 $CMND Clearmind Medicine Announces CNIPA Publication Of Patent For MEAI Compound In Depression Treatment $DOX Amdocs Signs Agreement With Vivo To Deliver OSS Project Modernization To Deploy Cloud-Native, Microservices-Based Release Of Service Orchestration, Service Activation $REPL Replimune Group shares are trading higher after the company announced it presented biomarker data and updated clinical data from the IGNYTE clinical trial of RP1 plus nivolumab. $TTE TotalEnergies And Google Have Signed A 15-year Power Purchase Agreement To Supply Google With A Total Volume Of 1.5 TWh Of Certified Renewable Electricity $IBM At The Annual Quantum Developer Conference, IBM Unveils Fundamental Progress On Its Path To Delivering Quantum Advantage By The End Of 2026 And Fault-tolerant Quantum Computing By 2029
0 · Reply
Main_Street_Risks
Main_Street_Risks Nov. 12 at 3:44 AM
$REPL FDA tea leaves. While the current resubmission will be reviewed under CBER, the appointment of Dr. Pazdur to CDER is probably not a good sign for this name...or really any applicant aggressively pursuing shortcuts to market...here is looking at you $IBRX While he can be credited for expediting oncology approvals, in recent years he has been advocating for tighter standards for approval, particularly for single arm trials and accelerated approvals. He was rumored to be the real force behind the REPL CRL.
1 · Reply
Sjpu
Sjpu Nov. 11 at 9:37 PM
$REPL offering pump and dump
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 11 at 8:57 PM
$SONN 5%[0%] $REPL -4%[5%] $BODI 3%[22%] $NUAI -3%[-15%] $WYFI 3%[-11%] most notable movement into the final minutes of trading.
0 · Reply
mv21970
mv21970 Nov. 11 at 8:57 PM
$QURE $CAPR $BHVN $REPL $SRPT all up big hmmm ... maybe VP will be fired again and this time he should take Makary with him hahaha
0 · Reply
PaixTrader
PaixTrader Nov. 11 at 7:06 PM
$SRPT — Note to future FDA leadership: Sarepta was badly mistreated under Vinay and Malarkey. We want our AAV vector platform designation restored and the black box warning removed. It’s time to right the wrongs, undo the damage they’ve done to the biotech sector, and replace politics with progress. The FDA under their watch became a mini fiefdom where agendas trumped science and true expedited review never happened. Everyone get ready to submit your letters to new FDA. $QURE $REPL
2 · Reply
Latest News on REPL
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Nov 7, 2025, 4:45 PM EST - 7 days ago

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Nov 6, 2025, 8:00 AM EST - 8 days ago

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Oct 20, 2025, 7:00 AM EDT - 25 days ago

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Oct 19, 2025, 8:00 AM EDT - 26 days ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Sep 21, 2025, 7:40 AM EDT - 7 weeks ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Replimune Provides Update Following Type A Meeting with FDA

Sep 18, 2025, 9:15 AM EDT - 2 months ago

Replimune Provides Update Following Type A Meeting with FDA

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Sep 13, 2025, 10:10 AM EDT - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Sep 5, 2025, 6:54 PM EDT - 2 months ago

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Sep 2, 2025, 9:46 PM EDT - 2 months ago

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Replimune Announces Type A Meeting Scheduled with FDA

Sep 2, 2025, 8:00 AM EDT - 2 months ago

Replimune Announces Type A Meeting Scheduled with FDA

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL

Aug 13, 2025, 4:39 PM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

Aug 13, 2025, 3:26 PM EDT - 3 months ago

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

Replimune Group: The Prospects For FDA Approval After Rejection

Aug 7, 2025, 10:08 AM EDT - 3 months ago

Replimune Group: The Prospects For FDA Approval After Rejection

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:00 AM EDT - 3 months ago

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Why Is Replimune Stock Trading Lower On Monday?

Aug 4, 2025, 12:43 PM EDT - 3 months ago

Why Is Replimune Stock Trading Lower On Monday?

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Aug 1, 2025, 10:51 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

Jul 30, 2025, 8:36 AM EDT - 3 months ago

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Jul 28, 2025, 8:36 AM EDT - 3 months ago

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jul 25, 2025, 5:04 PM EDT - 4 months ago

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

Jul 24, 2025, 8:07 AM EDT - 4 months ago

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

Jul 22, 2025, 2:56 PM EDT - 4 months ago

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Jul 22, 2025, 11:03 AM EDT - 4 months ago

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 11, 2025, 4:01 PM EDT - 4 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2025, 10:00 AM EDT - 5 months ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 6 months ago

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

May 22, 2025, 11:19 AM EDT - 6 months ago

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

May 22, 2025, 7:00 AM EDT - 6 months ago

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

May 16, 2025, 8:00 AM EDT - 6 months ago

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025, 4:01 PM EDT - 6 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

May 8, 2025, 5:00 AM EDT - 6 months ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

COYA

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Apr 28, 2025, 3:26 PM EDT - 7 months ago

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Replimune: A Misunderstood Contender In Oncolytics

Feb 12, 2025, 4:21 PM EST - 9 months ago

Replimune: A Misunderstood Contender In Oncolytics

TwongStocks
TwongStocks Nov. 14 at 1:43 PM
$REPL RTW filed a new 13G this morning disclosing beneficial ownership in REPL https://www.sec.gov/Archives/edgar/data/1493215/000149321525000047/xslSCHEDULE_13G_X01/primary_doc.xml 6,395,732 shares, 8.2%
0 · Reply
smart500
smart500 Nov. 13 at 9:03 PM
$REPL classic Yee Haw gitty up horse chart. Let's ride her to the 🌜😆
0 · Reply
_ReddBullyz
_ReddBullyz Nov. 12 at 3:05 PM
Picked up on some of @Invinc1ble calls lately and they’ve been 🔥 If you trade, he’s definitely worth a follow💯 $DNLI $GWH $IPDN $REPL Monitor;
0 · Reply
patatechaude
patatechaude Nov. 12 at 2:34 PM
$REPL Makary might go down with Prasad. He needs to let go.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 12 at 11:31 AM
WATCHLIST NOV 12 2025 $CMND Clearmind Medicine Announces CNIPA Publication Of Patent For MEAI Compound In Depression Treatment $DOX Amdocs Signs Agreement With Vivo To Deliver OSS Project Modernization To Deploy Cloud-Native, Microservices-Based Release Of Service Orchestration, Service Activation $REPL Replimune Group shares are trading higher after the company announced it presented biomarker data and updated clinical data from the IGNYTE clinical trial of RP1 plus nivolumab. $TTE TotalEnergies And Google Have Signed A 15-year Power Purchase Agreement To Supply Google With A Total Volume Of 1.5 TWh Of Certified Renewable Electricity $IBM At The Annual Quantum Developer Conference, IBM Unveils Fundamental Progress On Its Path To Delivering Quantum Advantage By The End Of 2026 And Fault-tolerant Quantum Computing By 2029
0 · Reply
Main_Street_Risks
Main_Street_Risks Nov. 12 at 3:44 AM
$REPL FDA tea leaves. While the current resubmission will be reviewed under CBER, the appointment of Dr. Pazdur to CDER is probably not a good sign for this name...or really any applicant aggressively pursuing shortcuts to market...here is looking at you $IBRX While he can be credited for expediting oncology approvals, in recent years he has been advocating for tighter standards for approval, particularly for single arm trials and accelerated approvals. He was rumored to be the real force behind the REPL CRL.
1 · Reply
Sjpu
Sjpu Nov. 11 at 9:37 PM
$REPL offering pump and dump
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 11 at 8:57 PM
$SONN 5%[0%] $REPL -4%[5%] $BODI 3%[22%] $NUAI -3%[-15%] $WYFI 3%[-11%] most notable movement into the final minutes of trading.
0 · Reply
mv21970
mv21970 Nov. 11 at 8:57 PM
$QURE $CAPR $BHVN $REPL $SRPT all up big hmmm ... maybe VP will be fired again and this time he should take Makary with him hahaha
0 · Reply
PaixTrader
PaixTrader Nov. 11 at 7:06 PM
$SRPT — Note to future FDA leadership: Sarepta was badly mistreated under Vinay and Malarkey. We want our AAV vector platform designation restored and the black box warning removed. It’s time to right the wrongs, undo the damage they’ve done to the biotech sector, and replace politics with progress. The FDA under their watch became a mini fiefdom where agendas trumped science and true expedited review never happened. Everyone get ready to submit your letters to new FDA. $QURE $REPL
2 · Reply
Smellmahass
Smellmahass Nov. 8 at 12:15 PM
$REPL Will trade this straddle in April. Approval here now is 50 50.
0 · Reply
Maddmike
Maddmike Nov. 7 at 9:09 PM
$REPL yea 👎 under $5 soon
0 · Reply
Halbalidiya
Halbalidiya Nov. 7 at 4:18 PM
$REPL shorting to 0. You are institutional exit liquidity
1 · Reply
garrettreid
garrettreid Nov. 7 at 3:00 AM
$CADL Another thrashing this afternoon in the WSJ of Vinay and the FDA (along with Tidmarsh) for moving the goal posts on life-saving treatments ($CADL), ($QURE), $REPL)
2 · Reply
Dragonfly41
Dragonfly41 Nov. 5 at 8:47 PM
$REPL CAPR e plodding
0 · Reply
Davidendz
Davidendz Nov. 5 at 7:00 PM
$ONCY, $REPL, worthy to check $BVAXF $BIOV.CSE the chart looks dead but context matters here. Tartaglia coming aboard isn't just another exec hire, dude brought real immunology pathway chops from his Sanofi days. That's exactly the validation piece they were missing all this time. Cap structure finally makes sense too after those conversions last quarter.
0 · Reply
Jay_Bingo
Jay_Bingo Nov. 5 at 6:32 PM
$REPL Iovance front line ORR and mDOR in Melanoma <3 treatments makes Replimmune IRRELEVANT $IOVA
0 · Reply
mv21970
mv21970 Nov. 5 at 4:34 PM
$BHVN imo the management should not spend another cent on trorizulole and also end the expanded access program because this FDA will just f**k them again like they did with $QURE $SRPT $REPL $CAPR etc .. if the patients want access they should write to Congress, Senate or Trump because that is the only language these guys and VP understands
0 · Reply
LongLongStock
LongLongStock Nov. 5 at 1:57 PM
$QURE $CAPR $REPL $BHVN the list will keep growing
0 · Reply
Dragonfly41
Dragonfly41 Nov. 4 at 5:39 PM
$REPL CAPR going up
0 · Reply
TopCharts
TopCharts Nov. 3 at 10:47 PM
$REPL now that SRPT trial failure is reported stock tanking let’s see how FDA handles failures from REPL and CAPR after CRL for lack of study.
1 · Reply
only1de
only1de Nov. 3 at 8:38 PM
$QURE $REPL $SRPT for sure!
0 · Reply